Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer’s Association International Conferences

2026-03-10 - 12:43

VANCOUVER, British Columbia & GRAPEVINE, Texas -- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the American Association of Geriatric Psychiatrists (AAGP), taking place April 16-20, 2026 and the Neuroscience Education Institute (NEI) Spring Congress, taking place May 1-3, 2026. Read More